Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis

Details

Serval ID
serval:BIB_024F78E3019E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis
Journal
European Journal of Neurology
Author(s)
Weder  C., Baltariu  G. M., Wyler  K. A., Gober  H. J., Lienert  C., Schluep  M., Radu  E. W., De Libero  G., Kappos  L., Duda  P. W.
ISSN
1351-5101 (Print)
Publication state
Published
Issued date
11/2005
Volume
12
Number
11
Pages
869-78
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Nov
Abstract
Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA-specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients clinically, by magnetic resonance imaging and by primary immunological assays. Fluctuation of GA-specific proliferative responses was significantly lower in treatment responders than in untreated patients, and GA-specific proliferative responses were increased during relapses. These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response.
Keywords
Adult Biological Markers/analysis Cytokines/*secretion Humans *Immune Tolerance Magnetic Resonance Imaging Middle Aged Multiple Sclerosis, Relapsing-Remitting/*drug therapy/immunology Peptides/*therapeutic use Prospective Studies Th2 Cells Treatment Outcome
Pubmed
Web of science
Create date
25/01/2008 12:46
Last modification date
20/08/2019 12:24
Usage data